Detalhe da pesquisa
1.
Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutation.
Br J Cancer
; 128(11): 2072-2080, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37012318
2.
ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer.
Ann Oncol
; 34(8): 645-659, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37269905
3.
Enrollment of older metastatic breast cancer patients in first-line clinical trials: 9-year experience of the large-scale real-life multicenter French ESME cohort.
Breast Cancer Res Treat
; 191(3): 577-587, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34984582
4.
Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial.
Ann Oncol
; 32(2): 197-207, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33186740
5.
Breast cancer and screening in persons with an intellectual disability living in institutions in France.
J Intellect Disabil Res
; 61(3): 266-278, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-27624823
6.
Impact of a tailored oral vitamin D supplementation regimen on serum 25-hydroxyvitamin D levels in early breast cancer patients: a randomized phase III study.
Ann Oncol
; 27(7): 1235-41, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27029707
7.
Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study.
Ann Oncol
; 27(9): 1725-32, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27436849
8.
Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study.
Ann Oncol
; 26(2): 325-32, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25467016
9.
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials).
Ann Oncol
; 26(5): 873-879, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25725046
10.
Incidence and outcome of brain and/or leptomeningeal metastases in HER2-low metastatic breast cancer in the French ESME cohort.
ESMO Open
; 9(5): 103447, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38703431
11.
Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients.
Ann Oncol
; 23(11): 2879-2884, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-22571858
12.
[Anti-HER2 vaccines: The HER2 immunotargeting future?]. / Vaccination anti-HER2 : l'avenir du ciblage immunologique de HER2 ?
Pathol Biol (Paris)
; 59(3): 173-82, 2011 Jun.
Artigo
em Francês
| MEDLINE | ID: mdl-19481373
13.
Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort.
ESMO Open
; 6(3): 100114, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33895695
14.
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials).
Ann Oncol
; 26(12): 2505-6, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26467471
15.
CinéBreast-factors influencing the time to first metastatic recurrence in breast cancer: Analysis of real-life data from the French ESME MBC database.
Breast
; 49: 17-24, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-31675683
16.
ERRα promotes breast cancer cell dissemination to bone by increasing RANK expression in primary breast tumors.
Oncogene
; 38(7): 950-964, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30478447
17.
Quality of life and comorbidity score as prognostic determinants in non-small-cell lung cancer patients.
Ann Oncol
; 19(8): 1458-1464, 2008 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-18356134
18.
[How to combine hormonotherapy and radiation treatment in adjuvant breast cancer?]. / Cancers du sein : comment associer l'hormonothérapie et la radiothérapie en situation adjuvante ?
Cancer Radiother
; 12(1): 37-41, 2008 Jan.
Artigo
em Francês
| MEDLINE | ID: mdl-18248833
19.
Magnetic resonance imaging in breast cancer management in the context of neo-adjuvant chemotherapy.
Crit Rev Oncol Hematol
; 132: 51-65, 2018 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-30447927
20.
Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients.
Eur J Cancer
; 95: 93-101, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29655061